Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus ORTIKOS.
ASMANEX TWISTHALER vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid